TrueBinding Announces Results of TB006 Phase 1b/2 Placebo Controlled Proof-of-Concept Trial Showing Improvement on the Primary Cognition and Function Endpoint in Patients with Mild to Severe Alzheimer’s Disease
FOSTER CITY, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) — TrueBinding Inc. a clinical-stage biotherapeutics company focused on pioneering the development of innovative monoclonal antibodies for the treatment of some of the most challenging neurodegenerative diseases and other serious diseases, today announced top line results from its Phase 1b/2 proof-of-concept trial of TB006, an investigational monoclonal antibody against Galectin-3 for the treatment of mild to severe Alzheimer’s disease (AD) with baseline Mini Mental State Examination (MMSE) scores of 2-24). The primary endpoint (CDR-SB*, a patient and caregiver combined assessment) showed improvement that trended toward significance (p=0.08), a startling finding given the one-month treatment duration. Key secondary endpoints also showed improvements that reached or trended toward statistically significant results.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.